title: Persistent life-threatening hemorrhage after administration of idarucizumab.
authors.affiliation: Emergency Medical Services, University of Maryland Medical Center, Baltimore, MD.
authors.forename: Hussain M
authors.initials: HM
authors.lastname: Alhashem
authors.affiliation: Emergency Medical Services, University of Maryland Medical Center, Baltimore, MD.
authors.forename: Carmen
authors.initials: C
authors.lastname: Avendano
authors.affiliation: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD.
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Hayes
authors.affiliation: Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD. Electronic address: mwinters@em.umaryland.edu.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Winters
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects*; D004378:Duodenal Diseases / Q000139:chemically induced* / Q000628:therapy; D004621:Embolization, Therapeutic; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D008297:Male; D017211:Treatment Failure
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000931:Antidotes; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran